Hartmut Eimermacher

4.4k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Hartmut Eimermacher is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Hartmut Eimermacher has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 12 papers in Oncology and 9 papers in Genetics. Recurrent topics in Hartmut Eimermacher's work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Acute Myeloid Leukemia Research (6 papers). Hartmut Eimermacher is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Acute Myeloid Leukemia Research (6 papers). Hartmut Eimermacher collaborates with scholars based in Germany, Netherlands and Switzerland. Hartmut Eimermacher's co-authors include Wolfgang Hiddemann, Michael Unterhalt, Bernhard Wörmann, Bernd Metzner, Martin Dreyling, Eva Hoster, Ulrich Dührsen, Hannes Wandt, Joerg Hasford and Marcel Reiser and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Hartmut Eimermacher

23 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Eva Hoster, Martin Dreyling et al. Blood profile →

Peers

Countries citing papers authored by Hartmut Eimermacher

Since Specialization

Citations

This map shows the geographic impact of Hartmut Eimermacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hartmut Eimermacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hartmut Eimermacher more than expected).

Fields of papers citing papers by Hartmut Eimermacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hartmut Eimermacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hartmut Eimermacher. The network helps show where Hartmut Eimermacher may publish in the future.

Co-authorship network of co-authors of Hartmut Eimermacher

This figure shows the co-authorship network connecting the top 25 collaborators of Hartmut Eimermacher. A scholar is included among the top collaborators of Hartmut Eimermacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hartmut Eimermacher. Hartmut Eimermacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia 2013 ·Annals of Hematology ·N. Niederle, (unknown), Leopold Balleisen, W. Heit, Wolfgang Knauf, (unknown), Werner Freier, Axel Hinke, Stefan Ibach, Hartmut Eimermacher	30
2	CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial 2013 ·Annals of Hematology ·(unknown), Claudia R. Binder, Marita Ziepert, Michael Pfreundschuh, Ulrich Dührsen, Hartmut Eimermacher, Ali Aldaoud, Andreas Rosenwald, Markus Loeffler, Norbert Schmitz, Lorenz Truemper	19
3	The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) 2008 ·Leukemia ·Christian Buske, Eva Hoster, Martin Dreyling, Hartmut Eimermacher, H. Wandt, Bernd Metzner, Roland J. Fuchs, (unknown), Bernhard J. Woermann, Karin Hohloch, (unknown), W-D Ludwig, (unknown), S. Schmitz, Michael Kneba, Marcel Reiser, Ullrich Graeven, Wolfram Klapper, Michael Unterhalt, Wolfgang Hiddemann	99
4	Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months 2008 ·Blood ·Christian Buske, Eva Hoster, Martin Dreyling, Roswitha Forstpointner, Michael Kneba, Norbert Schmitz, Rudolf Schmits, Bernd Metzner, Marcel Reiser, Eva Lengfelder, Bernhard J. Woermann, (unknown), Susanna Hegewisch‐Becker, Wolfgang E. Berdel, Georg Heß, Hartmut Eimermacher, Ali Aldaoud, M. Planker, Michael Unterhalt, Wolfgang Hiddemann	14
5	The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG) 2008 ·Blood ·Horst Mueller, Lucia Nogová, Dennis A. Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting	0
6	The Addition of Rituximab to First-Line Chemotherapy (R-CHOP) Results in Superior Response Rates, Time to Treatment Failure and Response Duration in Patients with Advanced Stage Mantle Cell Lymphoma: Long Term Results of a Randomized GLSG Trial 2008 ·Blood ·Eva Hoster, Michael Unterhalt, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar B. Steinhauer, Sonja Martin, E. Heidemann, Ali Aldaoud, Wolfgang Hiddemann, Martin Dreyling	21
7	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study. 2007 ·Blood ·Michael Lübbert, Björn Rüter, Rainer Claus, Mathias Schmid, Ulrich Germing, Hartmut Eimermacher, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Pierre W. Wijermans, Dietmar Pfeifer, Claudia Schmoor, Hartmut Döhner	19
8	A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma breakdown → 2007 ·Blood ·Eva Hoster, Martin Dreyling, Wolfram Klapper, Christian Gisselbrecht, Achiel Van Hoof, Hanneke C. Kluin‐Nelemans, Michael Pfreundschuh, Marcel Reiser, Bernd Metzner, Hermann Einsele, Norma Peter, Wolfram Jung, Bernhard Wörmann, Wolfgang Ludwig, Ulrich Dührsen, Hartmut Eimermacher, Hannes Wandt, Joerg Hasford, Wolfgang Hiddemann, Michael Unterhalt	621
9	CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggressive T-cell lymphomas (DSHNHL 2003–1): Feasibility and toxicity of a phase II trial of the German High Grade Non-Hodgkin’s Lymphoma Group DSHNHL 2006 ·Journal of Clinical Oncology ·Lorenz Trümper, Karin Hohloch, Marita Kloess, Ulrich Dührsen, Hartmut Eimermacher, A. Haas, Ali Aldaoud, Markus Loeffler, (unknown), Michael Pfreundschuh, Claudia R. Binder	6
10	Double Induction Containing Either Two Courses or One Course of High-Dose Cytarabine Plus Mitoxantrone and Postremission Therapy by Either Autologous Stem-Cell Transplantation or by Prolonged Maintenance for Acute Myeloid Leukemia 2006 ·Journal of Clinical Oncology ·Thomas Büchner, Wolfgang E. Berdel, Claudia Schoch, Torsten Haferlach, Hubert Serve, Joachim Kienast, Susanne Schnittger, Wolfgang Kern, Joëlle Tchinda, Albrecht Reichle, Eva Lengfelder, Peter Staib, Wolfgang Ludwig, Carlo Aul, Hartmut Eimermacher, Leopold Balleisen, Maria‐Cristina Sauerland, Achim Heinecke, Bernhard Wörmann, Wolfgang Hiddemann	122
11	Dose-Dense Rituximab in Combination with Biweekly CHOP-14 for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Phase-I/II and Pharmacokinetic Study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). 2006 ·Blood ·Viola Poeschel, Maike Nickelsen, Mathias Hänel, Stephan Kremers, Swen Weßendorf, Hartmut Eimermacher, Norma Peter, Michael Wenger, Marcel Reiser, Norbert Schmitz, Michael Pfreundschuh	8
12	Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) 2005 ·Journal of Clinical Oncology ·Georg Lenz, Martin Dreyling, Eva Hoster, Bernhard Wörmann, Ulrich Dührsen, Bernd Metzner, Hartmut Eimermacher, Andreas Neubauer, Hannes Wandt, Hjalmar B. Steinhauer, Sonja Martin, E. Heidemann, Ali Aldaoud, Reza Parwaresch, Joerg Hasford, Michael Unterhalt, Wolfgang Hiddemann	418
13	A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes 2004 ·Leukemia ·Michael Stadler, Ulrich Germing, (unknown), (unknown), R. Kuse, W.-K. Hofmann, Hubert Schrezenmeier, J Novotný, (unknown), Hartmut Eimermacher, Walter Verbeek, H. Kreipe, H. Heimpel, Carlo Aul, Arnold Ganser	100
14	Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). 2004 ·Blood ·Christian Buske, Martin Dreyling, Hartmut Eimermacher, (unknown), Michael Pfreundschuh, Bernd Metzner, Roland J. Fuchs, Bernhard J. Woermann, Lorenz Truemper, Georg Heß, Hannes Wandt, Wolf‐Dieter Ludwig, (unknown), (unknown), H.J. Weh, Stephan Schmitz, W. Schmiegel, Michael Unterhalt, Wolfgang Hiddemann	14
15	Chromosome aberrations are restricted to the CD56⁺, CD3⁻ tumour cell population in natural killer cell lymphomas: a combined immunophenotyping and FISH study 1999 ·British Journal of Haematology ·Yanming Zhang, Kit Fai Wong, Reiner Siebert, Peter Matthiesen, Svetlana Harder, Hartmut Eimermacher, Alfred C. Feller, Brigitte Schlegelberger	13
16	Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia 1998 ·Cancer ·Wolfgang Kern, Gerhard Behre, (unknown), Andrea Kerkhoff, (unknown), Hartmut Eimermacher, (unknown), Bernhard Wörmann, Thomas Büchner, Wolfgang Hiddemann	13
17	Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia 1998 ·Cancer ·(unknown), Wolfgang Kern, Gerhard Behre, (unknown), Andrea Kerkhoff, (unknown), Hartmut Eimermacher, (unknown), (unknown), (unknown), Wolfgang Hiddemann	46
18	Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia 1998 ·Annals of Hematology ·Wolfgang Kern, Carlo Aul, Georg Maschmeyer, R. Kuse, Andrea Kerkhoff, (unknown), Hartmut Eimermacher, (unknown), Bernhard Wörmann, Thomas Büchner, Wolfgang Hiddemann	18
19	Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. 1996 ·PubMed ·Michael Unterhalt, Richard Herrmann, Markus Tiemann, Reza Parwaresch, H. Stein, Lorenz Trümper, (unknown), (unknown), C. Tirier, Andreas Neubauer, M. Freund, E.D. Kreuser, (unknown), (unknown), Andreas Engert, (unknown), Hartmut Eimermacher, (unknown), Wolfgang Hiddemann	41
20	Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo 1993 ·Annals of Hematology ·Torsten Haferlach, W. Gaßmann, H. Löffler, Christian Jürgensen, (unknown), Wolfgang Ludwig, E. Thiel, Dagmar Haase, Christa Fonatsch, R. Becher, Brigitte Schlegelberger, M. R. Nowrousian, Eva Lengfelder, Hartmut Eimermacher, (unknown), D. Braumann, Georg Maschmeyer, P. Koch, Achim Heinecke, M. C. Sauerland, (unknown)	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact